

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SEN  
03 FEB 14 PM 3:

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Aventis Pharmaceuticals Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 801 Pennsylvania Avenue, NW, Suite 725			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20004			
4. Contact Name Ann Taylor	Telephone (202) 898-3183	E-mail (optional) Ann.Taylor@aventis.com	5. Senate ID # 56831
7. Client Name <input checked="" type="checkbox"/> Self self			6. House ID # 35186

**TYPE OF REPORT** 8. Year 2002 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_ 11. No Lobbying

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ <u>1,320,000.00</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033 Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162 Internal Revenue Code</p>
---	--

Signature \_\_\_\_\_

Printed Name and Title       Eddie D. Evans, vice President, Federal Government Relations      

LD-2 (REV. 6/98)

P/

Registrant Name Aventis Pharmaceuticals Inc. Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

S. 812, H.R. 1826, H Res. 517 "The Greater Access to Affordable Pharmaceuticals Act of 2001"

17. House(s) of Congress and Federal agencies contacted  Check if None

U. S. Senate  
U. S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	
Judy Cook	
Richard Hodge	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharm is part of Aventis SA. Aventis is interested in this bill to ensure that Medicare beneficiaries have access to a private sector based prescription drug benefit, and that the industry of U.S. pharmaceuticals is preserved.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, Vice President, Federal Government Relations



Registrant Name Aventis Pharmaceuticals Inc. Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare Drug Reimbursement proposals for Medicare Part B.

17. House(s) of Congress and Federal agencies contacted  Check if None

Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	
Judy Cook	
Ann Taylor	
Richard Hodge	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharm is part of Aventis SA. Aventis is interested in this proposal to ensure that reimbursement is fair and equitable for all stakeholders.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, Vice President, Federal Government Relations



Registrant Name Aventis Pharmaceuticals Inc. Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 5482 "Diabetes Prevention Access and Care Act"  
All Provisions

17. House(s) of Congress and Federal agencies contacted  Check if None

U. S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Ann Taylor	
Richard Hodge	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Avenits Pharm is part of Aventis SA. Aventis is interested in passage of diabetes legislation tha prevent diabetes, but if prevention fails ensure that diabetics have acces and services to control their disease.

Signature \_\_\_\_\_ Date \_\_\_\_\_



Registrant Name Aventis Pharmaceuticals Inc. Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

S. 2394, H.R. 4730 "A bill to amend the Federal Food, Drug and Cosmetic Act to require labeling containing information applicable to pediatric patients"  
All Provisions

17. House(s) of Congress and Federal agencies contacted  Check if None

U. S. Senate  
U. S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharm is part of Aventis SA. Aventis is interested in the implementation of P.L. 107-109, Pharmaceuticals for Children Act, as it was passed by Congress.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, Vice President, Federal Government Relations



Registrant Name Aventis Pharmaceuticals Inc. Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cot information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

Advocate congressional support to the USTR, to ensure the Doha mandate is responsive to the HIV/AIDS crisis and abused.

17. House(s) of Congress and Federal agencies contacted  Check if None

U. S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Avenits Phan is part of Aventis SA. Aventis is interested in this issue to ensure tht the TRIPS not abuse the international response to HIV/AIDS.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, Vice President, Federal Government Relations



Registrant Name Aventis Pharmaceuticals Inc. Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cot information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 826, H.R. 1720 "Improved Access to Osteoporosis Testing Act of 2001"  
All Provisions

17. House(s) of Congress and Federal agencies contacted  Check if None

U. S. Senate  
U. S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Phan is part of Aventis SA. Aventis is interested in this legislation to ensure tht Med beneficiaries receive screening for osteoporosis.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, Vice President, Federal Government Relations



Registrant Name Aventis Pharmaceuticals Inc. Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 1976 "National Cancer Act of 2002" S. 2955 "National Cancer Act of 2002"  
 All Provisions

17. House(s) of Congress and Federal agencies contacted  Check if None

U. S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ann Taylor	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmacia is part of Aventis SA. Aventis is interested in ensuring that this legislation provides with access to needed cancer products, and that providers are fairly reimbursed for cancer drugs.

Signature \_\_\_\_\_ Date \_\_\_\_\_



Registrant Name Aventis Pharmaceuticals Inc. Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 2965 "Quality of Care for Individuals With Cancer Act"  
All Provisions

17. House(s) of Congress and Federal agencies contacted  Check if None

U. S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ann Taylor	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Avenits Phan is part of Aventis SA. Aventis is interested in this legislation to ensure that pat access to needed cancer drugs and that providers are fairly reimbursed for

Signature Eddie D. Evans Date 2/14/03

Printed Name and Title Eddie D. Evans, Vice President, Federal Government Relations

